Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

They say lightning rarely strikes twice but Kezar Life Sciences has suffered its second clinical blow in as many months.

Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly ...

R327G is a topical gel treatment being analysed for diabetic foot infections. Credit: Olga Apanasenko/Shutterstock. Recce ...

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...

Longboard has commenced the Phase III DEEp OCEAN Study of bexicaserin for treating seizures linked to DEEs in two years and ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

The trial enrolled 145 individuals with baseline characteristics, such as gender and distribution of PNs, representative of the global adult NF1 patient population. Credit: TimeImage ...

Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine ...